A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1
Active, not recruiting
- Conditions
- Multiple Myeloma
- Registration Number
- NCT06163898
- Lead Sponsor
- Celgene
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Inclusion Criteria:<br><br>Participant has a history of RRMM, and must:<br><br> - Part A: Have previously received = 3 prior lines of anti-myeloma therapy.<br><br> - Part B and Part C: Have received 1 to 3 prior lines of anti-myeloma therapy.<br><br>Exclusion Criteria:<br><br>• Must not have previously received alnuctamab or mezigdomide.<br><br>Note: Other protocol-defined inclusion/exclusion criteria apply
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Number of participants with adverse events (AEs);Number of participants with serious AEs (SAEs);Number of participants with AEs leading to discontinuation;Number of deaths;Number of participants with Dose-limiting toxicities (DLTs);Overall Response Rate (ORR)
- Secondary Outcome Measures
Name Time Method Complete Response Rate (CRR);Very Good Partial Response Rate (VGPRR);Progression-free Survival (PFS);Time-to-Response (TTR);Duration of Response (DOR);Overall Survival (OS);ORR